Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2015 - 2026)
Syndax Pharmaceuticals (SNDX) recorded quarterly Income from Continuing Operations of 30641000.0 in Q1 2026, up 47.37% quarter-over-quarter from 58220000.0 in Q4 2025, and up 59.99% on a YoY basis from 19152281.97 in Q1 2025.
Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 30641000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 59.99% year-over-year to 30641000.0; the TTM figure through Mar 2026 stood at 204425000.0 (up 35.68% YoY), while the FY2025 annual figure was 250360000.0, up 20.16% from the prior year.
- Income from Continuing Operations was 30641000.0 for Q1 2026 at Syndax Pharmaceuticals, up from 58220000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 30641000.0 in Q1 2026 to a low of 89133000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 56037352.94 across 5 years, with a median of 52157000.0 in 2025.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations sank 140.78% in 2022, then surged 59.99% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 39088000.0 in 2022, then tumbled by 85.27% to 72418000.0 in 2023, then slipped by 23.08% to 89133000.0 in 2024, then soared by 34.68% to 58220000.0 in 2025, then soared by 47.37% to 30641000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 30641000.0 (Q1 2026), 58220000.0 (Q4 2025), and 52157000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn | -30.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.64 Mn |
| Dec 31, 2025 | -58.22 Mn |
| Sep 30, 2025 | -52.16 Mn |
| Jun 30, 2025 | -63.41 Mn |
| Mar 31, 2025 | -76.58 Mn |
| Dec 31, 2024 | -89.13 Mn |
| Sep 30, 2024 | -84.16 Mn |
| Jun 30, 2024 | -67.98 Mn |
| Mar 31, 2024 | -72.35 Mn |
| Dec 31, 2023 | -72.42 Mn |
| Sep 30, 2023 | -51.08 Mn |
| Jun 30, 2023 | -44.52 Mn |
| Mar 31, 2023 | -40.98 Mn |
| Dec 31, 2022 | -39.09 Mn |
| Sep 30, 2022 | -35.11 Mn |
| Jun 30, 2022 | -37.54 Mn |
| Mar 31, 2022 | -37.29 Mn |
| Dec 31, 2021 | 95.85 Mn |
| Sep 30, 2021 | -20.60 Mn |
| Jun 30, 2021 | -22.86 Mn |